Raj Malik, MD – G1 Therapeutics discusses G1 Therapeutics to present data showing myelopreservation benefits of Trilaciclib in patients with small cell lung cancer at the ASCO20 Virtual Scientific Program. http://investor.g1therapeutics.com/news-releases/news-release-details/g1-therapeutics-present-data-showing-myelopreservation-benefits
Author: Editor
Radek Spisek, Ph.D. SOTIO discusses SO-C101 displays strong anti-tumor effect in TC-1 and TRAMP-C2 tumor mice and in combination with PD-1 blockade prevents tumor development in a NK and CD8+ T cells dependent manner Summary: SO-C101 is a IL-15 superagonist being developed for the treatment of advanced solid tumors – currently in an ongoing Phase 1 trial (NCT04234113) – Poster shows new preclinical data detailing anti-tumor efficacy in tumor mouse models – SO-C101 monotherapy significant reduced tumor growth in early and advanced treatment settings – SO-C101 in combination with PD-1 inhibitors led to durable tumor response in a majority of…
Radek Spisek, Ph.D. SOTIO discusses SO-C101 displays strong anti-tumor effect in TC-1 and TRAMP-C2 tumor mice and in combination with PD-1 blockade prevents tumor development in a NK and CD8+ T cells dependent manner Summary: SO-C101 is a IL-15 superagonist being developed for the treatment of advanced solid tumors – currently in an ongoing Phase 1 trial (NCT04234113) – Poster shows new preclinical data detailing anti-tumor efficacy in tumor mouse models – SO-C101 monotherapy significant reduced tumor growth in early and advanced treatment settings – SO-C101 in combination with PD-1 inhibitors led to durable tumor response in a majority of…
Radek Spisek, Ph.D. SOTIO discusses SO-C101 displays strong anti-tumor effect in TC-1 and TRAMP-C2 tumor mice and in combination with PD-1 blockade prevents tumor development in a NK and CD8+ T cells dependent manner Summary: SO-C101 is a IL-15 superagonist being developed for the treatment of advanced solid tumors – currently in an ongoing Phase 1 trial (NCT04234113) – Poster shows new preclinical data detailing anti-tumor efficacy in tumor mouse models – SO-C101 monotherapy significant reduced tumor growth in early and advanced treatment settings – SO-C101 in combination with PD-1 inhibitors led to durable tumor response in a majority of…
Radek Spisek, Ph.D. SOTIO discusses SO-C101 displays strong anti-tumor effect in TC-1 and TRAMP-C2 tumor mice and in combination with PD-1 blockade prevents tumor development in a NK and CD8+ T cells dependent manner Summary: SO-C101 is a IL-15 superagonist being developed for the treatment of advanced solid tumors – currently in an ongoing Phase 1 trial (NCT04234113) – Poster shows new preclinical data detailing anti-tumor efficacy in tumor mouse models – SO-C101 monotherapy significant reduced tumor growth in early and advanced treatment settings – SO-C101 in combination with PD-1 inhibitors led to durable tumor response in a majority of…
Khalil Choucair, MD – The Kansas University School of Medicine discusses Liquid biopsy: A community-based oncology practice experience. #ASCO2020 https://meetinglibrary.asco.org/record/188007/abstract
Khalil Choucair, MD – The Kansas University School of Medicine discusses Liquid biopsy: A community-based oncology practice experience. #ASCO2020 https://meetinglibrary.asco.org/record/188007/abstract
Khalil Choucair, MD – The Kansas University School of Medicine discusses Liquid biopsy: A community-based oncology practice experience. #ASCO2020 https://meetinglibrary.asco.org/record/188007/abstract
Razelle Kurzrock, MD – UC San Diego Health discusses a Comprehensive analysis of HER2 status through genomic, transcription, and translation among 5,305 patients with diverse malignancies.
Razelle Kurzrock, MD – UC San Diego Health discusses a Comprehensive analysis of HER2 status through genomic, transcription, and translation among 5,305 patients with diverse malignancies.
Razelle Kurzrock, MD – UC San Diego Health discusses a Comprehensive analysis of HER2 status through genomic, transcription, and translation among 5,305 patients with diverse malignancies.
Jason Luke, MD, FACP, is an associate professor of medicine in the Division of Hematology/Oncology at the University of Pittsburgh School of Medicine and the director of the Cancer Immunotherapeutics Center within the UPMC Hillman Cancer Center Immunology and Immunotherapy Program discusses A phase I, first-in-human, open-label, dose-escalation study of MGD013.
Jason Luke, MD, FACP, is an associate professor of medicine in the Division of Hematology/Oncology at the University of Pittsburgh School of Medicine and the director of the Cancer Immunotherapeutics Center within the UPMC Hillman Cancer Center Immunology and Immunotherapy Program discusses A phase I, first-in-human, open-label, dose-escalation study of MGD013.
Jason Luke, MD, FACP, is an associate professor of medicine in the Division of Hematology/Oncology at the University of Pittsburgh School of Medicine and the director of the Cancer Immunotherapeutics Center within the UPMC Hillman Cancer Center Immunology and Immunotherapy Program discusses A phase I, first-in-human, open-label, dose-escalation study of MGD013
Jason Luke, MD, FACP, is an associate professor of medicine in the Division of Hematology/Oncology at the University of Pittsburgh School of Medicine and the director of the Cancer Immunotherapeutics Center within the UPMC Hillman Cancer Center Immunology and Immunotherapy Program, discusses A phase I, first-in-human, open-label, dose-escalation study of MGD013.
Total glossectomy is a surgical option for patients with advanced (stage IV cancers) or recurrent tongue cancer. Advanced cancer of the tongue has severe repercussions to function and survival of the affected patients. This procedure is most commonly performed for oncologic control. CASE REPORT The patient, a 53-year-old male affected by carcinoma of base of tongue, was referred to Dr. Mathan Mohan. After extensive clinical and laboratory examination, Dr. Mathan nominated the patient for Total Glossectomy (TG) with PMMC flap reconstruction. RESECTION The procedure of total glossectomy for surgical management of such locally advanced cancer of the tongue is always…
Buccal cancer involving masticator space grows rapidly and penetrates well with a high recurrence rate due its aggressive nature. The local recurrence rate is very high, and many patients are treated with palliative intent because of their eventual poor outcome. Results are poor because of inability to achieve negative margins in three dimensions. Also, the surgical clearance is difficult because of the extent of tumour spread in masticator space. Cancers originating from the masticator space, pterygoid plates or skull base, invade adjacent anatomical structures, thus surgical tumour resection becomes very challenging. CASE REPORT The present case describes the surgical management…
Juan Carlos Varela, MD AdventHealth discusses AdventHealth launches first-of-its-kind immunotherapy treatment, clinical trial for specific blood cancer patients.
Juan Carlos Varela, MD – AdventHealth discusses AdventHealth launches first-of-its-kind immunotherapy treatment, clinical trial for specific blood cancer patients
Juan Carlos Varela, MD AdventHealth discusses AdventHealth launches first-of-its-kind immunotherapy treatment, clinical trial for specific blood cancer patients.
Nicolas Poirier, Ph.D. – OSE Immunotherapeutics – discusses Identifies Monoclonal Antibody Antagonists of CLEC-1 as New Checkpoint Inhibitors of Immune Myeloid Cells in Immuno-Oncology and New Data Supporting Bispecific Antibody Checkpoint Inhibitor Platform (BiCKI®) and Bifunctional Therapy Targeting PD-1 and IL-7 (BiCKI®-IL-7) For Cancer Immunotherapy – What is the next step for this research?
Nicolas Poirier, Ph.D. – OSE Immunotherapeutics – discusses – Identifies Monoclonal Antibody Antagonists of CLEC-1 as New Checkpoint Inhibitors of Immune Myeloid Cells in Immuno-Oncology and New Data Supporting Bispecific Antibody Checkpoint Inhibitor Platform (BiCKI®) and Bifunctional Therapy Targeting PD-1 and IL-7 (BiCKI®-IL-7) For Cancer Immunotherapy.
David A. Reardon, MD Dana-Farber Cancer Institute discusses INO-5401 and INO-9012 in combination with cemiplimab REGN2810 in newly diagnosed glioblastoma GBM Interim results. What is the next step for this research?
David A. Reardon, MD Dana-Farber Cancer Institute discusses INO-5401 and INO-9012 in combination with cemiplimab REGN2810 in newly diagnosed glioblastoma GBM Interim results. – How will this affect clinicians today?
David A. Reardon, MD Dana-Farber Cancer Institute discusses What is the rationale in combining these agents together? – INO-5401 and INO-9012 in combination with cemiplimab REGN2810 in newly diagnosed glioblastoma GBM Interim results.
David A. Reardon, MD Dana-Farber Cancer Institute discusses INO-5401 and INO-9012 in combination with cemiplimab REGN2810 in newly diagnosed glioblastoma GBM Interim results.
Nicholas J. Vogelzang, MD Comprehensive Cancer Centers of Nevada discusses CX-2029, a PROBODY drug conjugate targeting CD71 (transferrin receptor): Results from a first-in-human study (PROCLAIM-CX-2029) in patients (Pts) with advanced prostate cancer and PROCLAIM-CX-072: Analysis of patients with prostate advanced solid tumors receiving long-term treatment with CX-072, a PD-L1 probody therapeutic, as a single agent or in combination with ipilimumab
Christoph Röllig, MD discusses For Acute Myeloid Leukemia, Genetic Testing Is Often Worth the Wait
Andrea Enzinger, MD Dana-Farber Cancer Institute discusses US trends and racial/ethnic disparities in opioid access among patients with poor prognosis cancer near end of life.
Nikhil C. Munshi, M.D of Dana Farber Cancer Institute discusses the positive results from pivotal KarMMa study of Ide-cel in MM Read here:Â https://news.bms.com/press-release/corporatefinancial-news/bristol-myers-squibb-and-bluebird-bio-present-updated-positive
Nikhil C. Munshi, M.D of Dana Farber Cancer Institute discusses the positive results from pivotal KarMMa study of Ide-cel in MM Read here:Â https://news.bms.com/press-release/corporatefinancial-news/bristol-myers-squibb-and-bluebird-bio-present-updated-positive
Nikhil C. Munshi, M.D of Dana Farber Cancer Institute discusses the positive results from pivotal KarMMa study of Ide-cel in MM Read here:Â https://news.bms.com/press-release/corporatefinancial-news/bristol-myers-squibb-and-bluebird-bio-present-updated-positive
Marwan Fakih, MD of City of Hope discusses CodeBreak 100: activity of AMG 510, a novel small molecule inhibitor of KRASG12C, in patients with advanced colorectal cancer Read here: https://meetinglibrary.asco.org/record/185490/abstract
Marwan Fakih, MD of City of Hope discusses CodeBreak 100: activity of AMG 510, a novel small molecule inhibitor of KRASG12C, in patients with advanced colorectal cancer Read here:Â https://meetinglibrary.asco.org/record/185490/abstract
Featuring David Gandara, MD and Johannes Kratz, MD Please visit www.oncocyte.com for more information on DetermaRx  2020 has ushered in two important milestones in early-stage lung cancer. First, CMS approved DetermaRx, a molecular test that identifies patients with Stage I-IIA non-squamous NSCLC who are at high risk of recurrence, and may benefit from adjuvant chemotherapy. Second, the ADAURA trial results, presented at ASCO, demonstrated the efficacy of osimertinib in EGFR-positive early-stage NSCLC. In this webinar, we will review these latest research findings as well as ongoing clinical trials on the use of chemotherapy, targeted therapy, and immunotherapy in early-stage…
Sudhir Manda, MD of Arizona Oncology discusses the long-term proteasome inhibition in multiple myeloma following an in-class transition from bortezomib to ixazomib.
Sudhir Manda, MD of Arizona Oncology discusses the long-term proteasome inhibition in multiple myeloma following an in-class transition from bortezomib to ixazomib.
Matthew P. Goetz, MD of Mayo Clinic @MayoClinic discusses acquired genomic alterations in circulating tumor DNA from patients receiving abemaciclib alone or in combination with endocrine therapy. Read here:Â https://meetinglibrary.asco.org/record/185090/abstract
Matthew P. Goetz, MD of Mayo Clinic @MayoClinic discusses acquired genomic alterations in circulating tumor DNA from patients receiving abemaciclib alone or in combination with endocrine therapy. Read here:Â https://meetinglibrary.asco.org/record/185090/abstract
Timothy A Yap, MD, PhD of MD Anderson Cancer Center @MDAndersonNews discusses AVID200, first-in-class TGF-beta 1 and 3 selective and potent inhibitor: Safety and biomarker results of a phase I monotherapy dose-escalation study in patients with advanced solid tumors. Read here:Â https://meetinglibrary.asco.org/record/187808/abstract
Timothy A Yap, MD, PhD of MD Anderson Cancer Center @MDAndersonNews discusses AVID200, first-in-class TGF-beta 1 and 3 selective and potent inhibitor: Safety and biomarker results of a phase I monotherapy dose-escalation study in patients with advanced solid tumors. Read here:Â https://meetinglibrary.asco.org/record/187808/abstract
Timothy A Yap, MD, PhD of MD Anderson Cancer Center @MDAndersonNews discusses AVID200, first-in-class TGF-beta 1 and 3 selective and potent inhibitor: Safety and biomarker results of a phase I monotherapy dose-escalation study in patients with advanced solid tumors. Read here:Â https://meetinglibrary.asco.org/record/187808/abstract
Matthew P. Goetz, MD of Mayo Clinic @MayoClinic discusses acquired genomic alterations in circulating tumor DNA from patients receiving abemaciclib alone or in combination with endocrine therapy Read here:Â https://meetinglibrary.asco.org/record/185090/abstract
Caron Jacobson, MD of Dana Farber Cancer Institute @DanaFarber discusses the interim analysis of zuma-5 presented at this year’s virtual ASCO. Read here:Â https://meetinglibrary.asco.org/record/186013/abstract
Nathan A. Pennell MD @n8pennell of Cleveland Clinic @CleClinicMD @ClevelandClinic discusses a phase I safety and feasibility study of neoadjuvant chemoradiation plus pembrolizumab followed by consolidation pembrolizumab in resectable stage IIIA non-small cell lung cancer. Read here:Â https://meetinglibrary.asco.org/record/184547/abstract
Nathan A. Pennell MD @n8pennell of Cleveland Clinic @CleClinicMD @ClevelandClinic discusses a phase I safety and feasibility study of neoadjuvant chemoradiation plus pembrolizumab followed by consolidation pembrolizumab in resectable stage IIIA non-small cell lung cancer. Read here:Â https://meetinglibrary.asco.org/record/184547/abstract
Lipika Goyal, MD of Massachusetts General Hospital @MassGeneralNews discusses the data for futibatinib in advanced intrahepatic cholangiocarcinoma. Read here:Â https://www.prnewswire.com/news-releases/taiho-oncology-announces-presentation-of-data-for-futibatinib-in-advanced-intrahepatic-cholangiocarcinoma-at-2020-asco-meeting-301068213.html?tc=eml_cleartime
Sagar Lonial, MD @SagarLonialMD of Winship Cancer Institute @WinshipAtEmory discusses ixazomib vs placebo maintenance for NDMM patients not undergoing autologous stem cell transplant. Read here:Â https://meetinglibrary.asco.org/record/186184/abstract
Sagar Lonial, MD @SagarLonialMD of Winship Cancer Institute @WinshipAtEmory discusses ixazomib vs placebo maintenance for NDMM patients not undergoing autologous stem cell transplant. Read here:Â https://meetinglibrary.asco.org/record/186184/abstract
Sagar Lonial, MD @SagarLonialMD of Winship Cancer Institute @WinshipAtEmory discusses ixazomib vs placebo maintenance for NDMM patients not undergoing autologous stem cell transplant. Read here: https://meetinglibrary.asco.org/record/186184/abstract